Loading...
XETR
1SXP
Market cap3.44bUSD
Jul 09, Last price  
19.96EUR
1D
13.28%
1Q
42.57%
IPO
-36.92%
Name

SCHOTT Pharma AG & Co KgaA

Chart & Performance

D1W1MN
XETR:1SXP chart
P/E
20.53
P/S
3.05
EPS
0.97
Div Yield, %
0.80%
Shrs. gr., 5y
Rev. gr., 5y
11.04%
Revenues
986m
+3.04%
584,229,000648,668,000821,144,000898,602,000957,091,000986,210,000
Net income
146m
-2.16%
77,480,000100,753,000125,379,000151,842,000149,685,000146,454,000
CFO
180m
-20.15%
104,397,000132,213,000182,123,000181,652,000225,326,000179,920,000
Dividend
Feb 04, 20260.18 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Globally, SCHOTT Pharma AG & Co. KGaA specializes in the development, manufacturing, and distribution of sophisticated containment and delivery systems specifically designed for injectable pharmaceuticals, catering to the needs of the pharmaceutical and biotechnology sectors. Their comprehensive product portfolio encompasses both polymer and glass options across various crucial categories, including syringes, ampoules, vials, and cartridges. Their extensive range of syringes features specialized solutions such as the syriQ series (including BioPure for biologics and silicone-free variants) crafted from glass, ideal for vaccines and sensitive biologics, alongside the versatile polymer-based SCHOTT TOPPAC line, tailored for applications from cosmetic treatments and deep-cold storage to infusion therapy and delicate drugs. For cartridges, SCHOTT Pharma provides the cartriQ pharmaceutical glass series, designed for peptide, protein, and large-volume injectables, as well as double-chamber options for lyophilized drugs and break-resistant variants, supplemented by their TopLine and StandardLine offerings. Vial solutions include the adaptiQ pharmaceutical glass vial for general injectables, the EVERIC range focused on drug stability (pure, care for pH, strong & smooth for filling lines), SCHOTT Type I plus for specific formulations, and TopLyo to prevent fogging in lyophilized drugs, alongside their TopLine and StandardLine vials. The ampoule selection features easyOPC for convenient opening, Anti-Counterfeiting ampoules for enhanced security, and their dependable StandardLine options. Established in 1884 and based in Mainz, Germany, SCHOTT Pharma AG & Co. KGaA functions as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.
IPO date
Sep 28, 2023
Employees
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFY
2025‑092024‑092023‑092022‑092021‑092020‑09
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT